يعرض 1 - 10 نتائج من 17 نتيجة بحث عن '"Rinath Jeselsohn"', وقت الاستعلام: 0.71s تنقيح النتائج
  1. 1
    265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

    المؤلفون: Sahirzeeshan Ali, E. Ainscow, Ash Bahl, Sagar Sardesai, Janine Mansi, H-T. Arkenau, M. Lehnert, P. Richards, Simon Lord, S. McIntosh, Glen Clack, R. C. Coombes, Sacha J Howell, Laura M. Kenny, Z. Mitri, Rinath Jeselsohn, Joyce O'Shaughnessy, Matthew G Krebs, Carlo Palmieri, William J. Gradishar

    المصدر: Annals of Oncology. 32:S477-S478

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Fulvestrant, business.industry, HER2 negative, Hematology, medicine.disease, Breast cancer, Hormone receptor, Internal medicine, medicine, In patient, Cyclin-dependent kinase 7, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::08b6b9a5d594a26b1180a26321d43ebdTest
    https://doi.org/10.1016/j.annonc.2021.08.548Test


    أضف إلى المفضلة
  2. 2
    The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

    المؤلفون: Agostina Nardone, Rachel Schiff, Henry Brown, Meghana V. Trivedi, Martin Shea, Mark Pilling, Jamunarani Veeraraghavan, Chandandeep Nagi, Rinath Jeselsohn, Carmine De Angelis, Oona Delpuech, Maria Letizia Cataldo, Tamika Mitchell, C. Kent Osborne, Mothaffar F. Rimawi, Hazel M. Weir, Gary C. Chamness, Xiaoyong Fu, Susan G. Hilsenbeck

    المساهمون: Pilling, Mark [0000-0002-7446-6597], Apollo - University of Cambridge Repository, Nardone, A., Weir, H., Delpuech, O., Brown, H., De Angelis, C., Cataldo, M. L., Fu, X., Shea, M. J., Mitchell, T., Veeraraghavan, J., Nagi, C., Pilling, M., Rimawi, M. F., Trivedi, M., Hilsenbeck, S. G., Chamness, G. C., Jeselsohn, R., Osborne, C. K., Schiff, R.

    المصدر: British Journal of Cancer

    مصطلحات موضوعية: Cancer Research, Indoles, Neoplasms, Hormone-Dependent, Breast Neoplasms, Article, 03 medical and health sciences, chemistry.chemical_compound, Mice, MCF-7 Cell, 0302 clinical medicine, Breast cancer, Cinnamate, In vivo, medicine, Animals, Humans, Receptor, skin and connective tissue diseases, Fulvestrant, Cancer, Cell Proliferation, Estradiol, Animal, Cell growth, Estrogens, medicine.disease, Estrogen, Metastatic breast cancer, 3. Good health, Tamoxifen, Oncology, chemistry, Receptors, Estrogen, Indole, Cell culture, Cinnamates, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer research, MCF-7 Cells, Heterografts, Female, Growth inhibition, Heterograft, Breast Neoplasm, Human, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1307add3c66d5075ec69b579adb4aedTest
    http://europepmc.org/articles/PMC6353941Test


    أضف إلى المفضلة
  3. 3
    A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study

    المؤلفون: Muralidhar Beeram, Erika Hamilton, Philippe Aftimos, Xuejing Aimee Wang, Meena Okera, Sung-Bae Kim, Peter A. Kaufman, Kalyan Banda, Tarek Meniawy, Joohyuk Sohn, Sarah Sammons, Cynthia X. Ma, Suzanne R.L. Young, Rinath Jeselsohn, J. Thaddeus Beck, Kathleen K. Harnden, Komal Jhaveri, Cristina Saura, Kan Yonemori, Elgene Lim

    المصدر: Journal of Clinical Oncology. 39:1050-1050

    مصطلحات موضوعية: Cancer Research, Oncology, Fulvestrant, business.industry, Advanced breast, Cancer research, Estrogen receptor, Medicine, Cancer, First in human, business, medicine.disease, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9a9341ea6d19ca46f1f9a7a6038bdf1aTest
    https://doi.org/10.1200/jco.2021.39.15_suppl.1050Test


    أضف إلى المفضلة
  4. 4
    Are We Ready to Use ESR1 Mutations in Clinical Practice

    المؤلفون: Rinath Jeselsohn

    المصدر: Breast Care. 12:309-313

    مصطلحات موضوعية: 0301 basic medicine, medicine.drug_class, Estrogen receptor, Review Article, 03 medical and health sciences, 0302 clinical medicine, Medicine, Aromatase, biology, Fulvestrant, business.industry, medicine.disease, Metastatic breast cancer, body regions, Clinical trial, 030104 developmental biology, Oncology, Estrogen, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Surgery, business, Estrogen receptor alpha, Tamoxifen, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c30b1b324f668483a8057a0dace9f7dTest
    https://doi.org/10.1159/000481428Test


    أضف إلى المفضلة
  5. 5
    A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma

    المؤلفون: Maria Koehler, Angela DeMichele, William T. Barry, Rinath Jeselsohn, Beth Overmoyer, EP Winer, Adrienne G. Waks, Kathy D. Miller, Harold J. Burstein, Hope S. Rugo, C Huang Bartlett, Therese M. Mulvey, H Guo, Erica L. Mayer, Steven E. Come

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology. 30(9)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, medicine.medical_specialty, Pyridines, Receptor, ErbB-2, Population, Breast Neoplasms, Palbociclib, Disease-Free Survival, Piperazines, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cumulative incidence, Neoplasm Invasiveness, education, Fulvestrant, Protein Kinase Inhibitors, Neoplasm Staging, education.field_of_study, Estradiol, business.industry, Hematology, Middle Aged, medicine.disease, Metastatic breast cancer, Discontinuation, 030104 developmental biology, Tolerability, Receptors, Estrogen, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Feasibility Studies, Female, business, Receptors, Progesterone, Febrile neutropenia

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92854b34d679e7f53cb104cae812975Test
    https://pubmed.ncbi.nlm.nih.gov/31250880Test


    أضف إلى المفضلة
  6. 6
    KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance

    المؤلفون: Sébastien Vigneau, Ofir Cohen, Guillermo Peluffo, David J. Maloney, Jacob D. Jaffe, Piotr Sicinski, Alexander Meissner, Alexander A. Gimelbrant, Ganesha Rai, Franziska Michor, Madhu Lal-Nag, Rinath Jeselsohn, Kyomi J. Igarashi, Thomas O. McDonald, Ajit Jadhav, Shawn Egri, Anne Fassl, Kunihiko Hinohara, Stephen C. Kales, Kimiyo N. Yamamoto, Malvina Papanastasiou, Hua-Jun Wu, Thomas Madsen, Lina Ding, Anton Simeonov, Nikhil Wagle, Kornelia Polyak, Myles Brown

    المصدر: Cancer Cell

    مصطلحات موضوعية: 0301 basic medicine, Jumonji Domain-Containing Histone Demethylases, Cancer Research, Histone H3 Lysine 4, Estrogen receptor, Breast Neoplasms, Biology, Article, Transcriptome, Genetic Heterogeneity, 03 medical and health sciences, 0302 clinical medicine, Estrogen Receptor Modulators, Cell Line, Tumor, Exome Sequencing, Humans, Epigenetics, Histone demethylase activity, Fulvestrant, Estradiol, Genetic heterogeneity, Nuclear Proteins, Cell Biology, Repressor Proteins, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, KDM5A, MCF-7 Cells, Cancer research, biology.protein, Demethylase, Female, Retinoblastoma-Binding Protein 2

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7feebae35ebb3a658a47cb70d954c6cTest
    https://hdl.handle.net/21.11116/0000-0003-4DD4-821.11116/0000-0003-4DD2-ATest


    أضف إلى المفضلة
  7. 7
    Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine

    المؤلفون: Rinath Jeselsohn, Rachel Schiff

    المصدر: Cancer discovery. 8(11)

    مصطلحات موضوعية: 0301 basic medicine, Pyridines, Drug Resistance, Breast Neoplasms, Drug resistance, Computational biology, Palbociclib, Biology, Somatic evolution in cancer, Piperazines, Article, Circulating Tumor DNA, Clonal Evolution, 03 medical and health sciences, 0302 clinical medicine, Acquired resistance, medicine, Humans, Precision Medicine, Fulvestrant, Cancer, Precision medicine, medicine.disease, 030104 developmental biology, Oncology, Circulating tumor DNA, 030220 oncology & carcinogenesis, Mutation, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78cd00f0ad81840ec6511c1c4ff8637fTest
    https://pubmed.ncbi.nlm.nih.gov/30206110Test


    أضف إلى المفضلة
  8. 8
    The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

    المؤلفون: Emad Tajkhorshid, Myles Brown, David J. Hosfield, Yang Shen, Sarat Chandarlapaty, Teresa A. Martin, Christopher G. Mayne, Patrick R. Griffin, Mostafa Karimi, Jason Nowak, Gilles Buchwalter, Ross Han, Venkatasubramanian Dharmarajan, Jerome C. Nwachukwu, John A. Katzenellenbogen, Weiyi Toy, Kathryn E. Carlson, C.E. Fowler, René Houtman, Muriel Laine, Kendall W. Nettles, Rinath Jeselsohn, Sean W. Fanning, Geoffrey L. Greene

    المصدر: eLife, Vol 7 (2018)
    eLife

    مصطلحات موضوعية: 0301 basic medicine, Indoles, Pyridines, medicine.medical_treatment, Estrogen receptor, Ligands, Piperazines, Protein Structure, Secondary, acquired drug resistance, 0302 clinical medicine, selective estrogen receptor Degrader, Biology (General), skin and connective tissue diseases, Fulvestrant, Cancer Biology, General Neuroscience, General Medicine, 3. Good health, 030220 oncology & carcinogenesis, MCF-7 Cells, Medicine, Female, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Protein Binding, Research Article, Human, estrogen receptor, Selective Estrogen Receptor Modulators, QH301-705.5, Science, Breast Neoplasms, Palbociclib, General Biochemistry, Genetics and Molecular Biology, Bazedoxifene, 03 medical and health sciences, Structure-Activity Relationship, Breast cancer, breast cancer, Protein Domains, medicine, Humans, General Immunology and Microbiology, hormone therapy, business.industry, Estrogen Receptor alpha, medicine.disease, Antiestrogen, Tamoxifen, 030104 developmental biology, Drug Resistance, Neoplasm, Raloxifene Hydrochloride, Mutation, Cancer research, Mutant Proteins, Hormone therapy, business, Estrogen receptor alpha, ESR1 Somatic Mutation

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a690f4a60a1ddcc6a9caac9dd90769d1Test
    https://elifesciences.org/articles/37161Test


    أضف إلى المفضلة
  9. 9
    Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer

    المؤلفون: Jiani Hu, Bilal A. Siddiqui, Rinath Jeselsohn, Matthew Pun, William T. Barry, Paul Kirschmeier, Nan Lin, Pasi A. Jänne, Eric P. Winer, Nikhil Wagle, Ian E. Krop, Myles Brown, Yanan Kuang, MacIntosh Cornwell, Gilles Buchwalter, Cloud P. Paweletz, Melissa E. Hughes

    المصدر: NPJ Breast Cancer
    npj Breast Cancer, Vol 4, Iss 1, Pp 1-10 (2018)

    مصطلحات موضوعية: 0301 basic medicine, medicine.drug_class, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Aromatase, Aromatase inhibitor, biology, Fulvestrant, business.industry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Metastatic breast cancer, Primary tumor, 3. Good health, body regions, 030104 developmental biology, Oncology, Estrogen, 030220 oncology & carcinogenesis, biology.protein, Cancer research, business, Estrogen receptor alpha, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95eae3fb13e3d129d116d1a5b37b512Test
    http://europepmc.org/articles/PMC6072793Test


    أضف إلى المفضلة
  10. 10
    Abstract B16: Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER+) breast cancer patients

    المؤلفون: C. Guarducci, Gabriella Cohen, Agostina Nardone, Myles Brown, Franziska Michor, Weihan Liu, Rinath Jeselsohn, Shayna Stein

    المصدر: Cancer Research. 80:B16-B16

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Combination therapy, Fulvestrant, business.industry, Cancer, Palbociclib, medicine.disease, Clinical trial, chemistry.chemical_compound, Breast cancer, chemistry, Internal medicine, Medicine, Dosing, business, Abemaciclib, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e477fd0549d606fc96ed8ae6f6238c43Test
    https://doi.org/10.1158/1538-7445.camodels2020-b16Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث